





































































































(whether	 on	 or	 off	 ART)	 by	 estimating	 the	 degree	 to	 which	 the	 coverage	 of	 ART	 in	 that	 sub-
population	decreases	the	overall	average	transmission	risk	across	all	HIV-infected	PWID	whether	on	
or	off	ART.	We	denote	 this	as	 the	prevention	effectiveness	of	ART	 for	 that	 sub-population,	which	
depends	on	both	the	coverage	of	ART	amongst	those	PWID	and	the	degree	to	which	ART	decreases	




Assuming	 a	 certain	 coverage	 of	 ART	 amongst	 those	 not	 on	 OST,	 and	 level	 of	 viral	 suppression	
amongst	 those	 on	 ART,	 synthesised	 effect	 estimates	 from	 our	 recent	 systematic	 review[24]	were	





HIV	 infectivity	 achieved	 through	ART	 by	 these	 PWID.	 These	 calculations	 utilised	 existing	 observed	




relative	decrease	 in	HIV	 infectivity	 for	virally	suppressed	or	unsuppressed	PWID	on	ART	were	then	
averaged	 across	 the	 proportion	 virally	 suppressed	 or	 not	 for	 different	 intervention	 combinations,	
and	 used	 to	 estimate	 the	 prevention	 effectiveness	 of	 ART	 for	 PWID	 on	 and	 off	 OST,	 and	 at	 the	
population-level	 for	 specified	OST	 coverage	 levels	 as	well	 as	 if	OST	had	not	 been	 introduced.	 The	
relative	increase	in	the	prevention	effectiveness	of	ART	for	PWID	on	OST	compared	to	PWID	off	OST	
was	 calculated,	 as	 was	 the	 relative	 increase	 in	 the	 overall	 prevention	 effectiveness	 of	 ART	 for	








off	 OST	 allowed	 improvements	 in	 ART	 coverage	 amongst	 PWID	 on	OST	 to	 improve	 ART	 coverage	











into	 the	 HIV-infected	 compartment	 is	 set	 to	 maintain	 a	 constant	 population	 before	 ART	 was	
introduced.	Recruitment	onto	OST	occurs	 independently	of	ART	 status.	When	 initiated	on	 to	OST,	
PWID	enter	short-term	OST,	from	which	they	either	leave	OST	or	transition	to	long-term	OST.	PWID	
leave	 long-term	 OST	 at	 a	 reduced	 rate.	 When	 on	 OST,	 recruitment	 onto	 ART	 is	 increased	 and	















and	 mortality,	 with	 all	 parameter	 estimates	 given	 in	 Table	 1.	 A	 wide	 range	 was	 used	 for	 the	
combined	 rate	 of	 injecting	 cessation	 and	 HIV-unrelated	 mortality	 (5-25%	 per	 year)	 because	 of	
uncertainty	 in	 the	 injecting	 duration	 across	 settings[22,	 28-30].	 HIV-related	mortality[31,	 32]	 was	
assumed	to	reduce	by	66-80%	if	on	ART[33-37].	Estimates	for	the	baseline	rate	of	ART	retention	for	







over	 6-12	 months[39].	 To	 model	 attrition	 from	 OST	 over	 longer	 time	 periods,	 we	 combined	 five	
international	datasets	which	captured	OST	retention	for	over	a	year	([40-43]	and	Matthew	Hickman	
personal	 communication).	 These	 data	 were	 used	 to	 give	 a	 range	 of	 possible	 trajectories	 (and	
corresponding	OST	retention	rates)	for	the	long-term	retention	of	PWID	on	OST	(Figure	S2	and	S3),	





To	 incorporate	 uncertainty,	 1000	 parameter	 sets	 were	 randomly	 sampled	 from	 the	 static	 model	
parameter	 distributions	 given	 in	 Table	 1.	 For	 each	 sampled	 parameter	 set,	 and	 a	 wide	 range	 of	
baseline	ART	coverage	levels	(10-90%	when	no	OST),	the	model	projected	the	absolute	and	relative	
increase	in	the	prevention	effectiveness	of	ART	for	someone	on	OST	compared	to	someone	not	on	


























A	 linear	 regression	 analysis	 of	 covariance	 (ANCOVA)[44]	 was	 undertaken	 to	 determine	 which	
parameter	 uncertainties	 contribute	 most	 to	 variability	 in	 the	 dynamic	 model’s	 projections	 of	 the	
relative	increase	in	population-level	prevention	effectiveness	of	ART	for	an	OST	coverage	of	40%	and	
baseline	ART	coverage	of	40%.	The	proportion	of	the	model’s	outcome	sum-of-squares	contributed	

































levels,	whereas	 the	 dynamic	model	 predicts	 a	 34.6%	 (20.3-49.4%),	 27.3%	 (16.2-40.1%)	 and	 17.3%	



























































































































Variable	or	parameter	 Symbol	 Value	(range	used)	 Source	and	comments	
Parameters	for	static	model	 	 	 	
ART	 coverage	 at	 baseline	 without	 effect	 of	
OST	
𝑥	 0	-	100%	 Varied	for	different	ART	scenarios	















































OST	parameters	 	 	 	
Recruitment	rate	onto	OST	per	year	 𝜀	 To	fit:	0-100%	 Varied	to	fit	different	OST	coverage	
scenarios	



































































(2a)	Absolute	increase	 	 	 	 	 (2b)	Relative	increase	
		
Figure	2.	Absolute	(2a)	and	relative	(2b)	increase	in	the	prevention	effectiveness	of	ART	for	PWID	on	
OST	 compared	 to	PWID	off	OST.	 These	projections	hold	 irrespective	of	 the	 level	 of	OST	 coverage.	
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